Tissue Expression and Serum Levels of HER-2/neu in Patients with Breast Cancer

Oncology (Switzerland)

Volumn 54, Issue 6, 1997, Pages 475-481

  Krainer, Michael ^a   Brodowicz, Thomas ^a   Zeillinger, Robert ^b   Wiltschke, Christoph ^a   Scholten, Christine ^a   Seifert, Michael ^c   Kubista, Ernst ^c   Zielinski, Christoph C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Molecular Oncology Group   (Austria)

^c Ebene 10   (Austria)

Author keywords

Breast cancer; CA15 3; CEA; HER 2 neu; Prognosis; Soluble HER 2 neu; Tumor marker

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER GENETICS; CANCER STAGING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TUMOR VOLUME;

BREAST NEOPLASMS; CA-15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 0030775807     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227606     Document Type: Article

References (29)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 1987:235:177-182.
2. Lupu R, Colomer R, Kannan B, Lippman ME: Characterization of a growth factor that binds exclusively to the crbB-2 receptor and induces cellular responses, Proc Natl Acad Sci USA 1992:89:2287-2291.
3. Harris AL, Nicholson S, Sainsbury R, Wright C, Famdon J: Epidermal growth factor receptor and other oncogenes as prognostic markers, Monogr Natl Cancer Inst 1992; 11:181-187.
4. Horiguchi J, lino Y, Takei H, Yokoe T, Ishida T, Morishita Y: Immunohistochemical study on the expression of c-crbB-2 oncoprotein in breast cancer, Oncology 1994;51:47-51.
5. Barnes DM, Meyer JS, Gonzalez JG, Gullick WJ, Millis RR: Relationship between c-crbB-2 immunoreactivity and thymidine labelling index in breast carcinoma in situ, Breast Cancer Res Treat 1991;18:11-17.
6. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ: Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer, Int J Cancer 1991:49:650-655.
7. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udovc J, Ullrich A: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer, Science 1989:244:707-712.
8. Tandon AK, Clark GM, Chamness GC, Ullrich A, McGuire WL: HER-2/neu oncogene protein and prognosis in breast cancer, J Clin Oncol 1989;7:1120-1128.
9. O'Reilly SM, Barnes DM, Camplejohn RS, Bartkova J, Gregory WM, Richards MA: The relationship between c-crbB-2 expression, S-phase fraction and prognosis in breast cancer, Br J Cancer 1991;63:444-446.
10. Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer, J Clin Oncol 1990;8:103-112.
11. Toikkanen S, Helin H, Isola J, Joensuu H: Prognostic significance of HER-2 oncoprotein expression in breast cancer: A 30-ycar follow-up, J Clin Oncol 1992; 10:1044-1048.
12. Scshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, Kitchen P: Clinical significance of HER-2/ncu oncogene amplification in primary breast cancer, The South Australian Breast Cancer Study Group, J Clin Oncol 1993:11: 1936-1942.
13. Smith K, Houlbrook S, Grecnall M, Carmichael J, Harris AL: Topoisomerase II alpha coamplification with erbB2 in human primary breast cancer and breast cancer cell lines: Relationship to nt-AMSA and mitoxantrone sensitivity, Oncogene 1993;8:933-938.
14. Tsai CM, Chang KT, Pemg RP, Mitsudomi T, Chen MH, Kadovama C, Gazdar AF: Correlation of intrinsic chcmoresistance of non-small-cell lung cancer cell lines with HER-2/ncu gene expression but not with ras gene mutations, J Natl Cancer Inst 1993:85:897-901.
15. Muss HB, Thor AD, Berry DA, Kute T, Liu ET, Koemer F, Cirrincione CT, Budman DR, Wood WC, Barcos M, Henderson IC: c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer, N Engl J Med 1994;330:1260-1266.
16. Leitzcl K, Teramoto Y, Sampson E, Mauceri J, Langton BC, Demers L, Podczaski E, Harvey H, Shambaugh S, Volas G, Weaver S, Lipton A: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients, J Clin Oncol 1992; 10:1436-1443.
17. Narita T, Funahashi H, Satoh Y, Takagi H: c-erbB-2 protein in the sera of breast cancer patients, Breast Cancer Res Treat 1993:24:97-102.
18. Kynast B, Binder L, Marx D, Zoll B, Schmoll HJ, Oellerich M, Schaucr A: Determination of a fragment of the c-erbB-2 translational product pi 85 in scrum of breast cancer patients, J Cancer Res Clin Oncol 1993; 119:249-252.
19. Wu JT, Astill ME, Gagon SD, Bry son L: Measurement of c-erbB-2 proteins in sera from patients with carcinomas and in breast tumor tissue cytosols: Correlation with serum tumor markers and membrane-bound oncoprotein, J Clin Lab Anal 1995;9:151-165.
20. Isola JJ, Holli K, Oksa H, Teramoto Y, Kal-lionicmi OP: Elevated erbB-2 oncoprotein levels in prcoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer, Cancer 1994.73:652-658.
21. Press MF, Hung G, Godolphin W, Slamon DJ: Sensitivity of HER-2/neu antibodies in archival tissue samples: Potential source of error in immunohistochemical studies of oncogene expression, Cancer Res 1994:54:2771-2777.
22. Zeillingcr R, Schneeberger Ch, Speiser P: Rapid quantitative analysis of differential PCR products by high-performance liquid chromatography, Biotechniques 1993:15:89-95.
23. Okada N, Ohshio G, Yamaki K, Imamura T, Imamura M: Elevated serum c-crbB-2 protein levels in patients with pancreatic cancer: Correlation to metastasis and shorter survival, Oncology 1995:52:392-396.
24. Vogel W, Kath R, Kosmehl H, Olschowsky E, Hoffkcn K: The neu oncogene product in serum and tissue of patients with metastatic gastrointestinal carcinomas, J Cancer Res Clin Oncol 1996:122:118-121.
25. Zabrecky JR, Lam T, McKenzie SJ, Carney W: The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chcm 1991:266: 1716-1720.
26. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G, Colnaghi MI: The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage, Oncogene 1993;8:2917-2923.
27. Pupa SM, Menard S, Andreola S, Colnaghi MI: Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients, Cancer Res 1993;53:5864-5866.
28. Rubin LA, Jay G, Nelson DL: The released interleukin 2 receptor binds interleukin 2 efficiently, J Immunol 1986;137:3841-3844.
29. Wiltschkc C, Tyl E, Speiser P, Steiningcr A, Zeillinger R, Kury F, Czerwenka K, Kubista E, Preis P, Krainer M, Zielinski CC: Increased natural killer cell activity correlates with low or negative expression of the HER-2/neu oncogene in patients with breast cancer, Cancer 1994:73:135-139.